Dengue vaccines: dawning at last?

[1]  P. Pitisuttithum,et al.  Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial , 2014, The Lancet.

[2]  P. MacAry,et al.  Dengue: Challenges for Policy Makers and Vaccine Developers , 2014, Current Infectious Disease Reports.

[3]  S. Yoksan,et al.  Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand , 2014, Virology Journal.

[4]  Stephen J. Thomas,et al.  Current issues in dengue vaccination , 2013, Current opinion in infectious diseases.

[5]  S. Halstead.  Identifying protective dengue vaccines: guide to mastering an empirical process. , 2013, Vaccine.

[6]  A. Wilder-Smith,et al.  Epidemiology of dengue: past, present and future prospects , 2013, Clinical epidemiology.

[7]  John S. Brownstein,et al.  The global distribution and burden of dengue , 2013, Nature.

[8]  Saravudh Suvannadabba,et al.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial , 2012, The Lancet.

[9]  L. Shek,et al.  Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years , 2012, Human Vaccines & Immunotherapeutics.

[10]  Kenneth G. C. Smith,et al.  The Structural Basis for Serotype-Specific Neutralization of Dengue Virus by a Human Antibody , 2012, Science Translational Medicine.

[11]  M. Diamond,et al.  Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions , 2012, Proceedings of the National Academy of Sciences.

[12]  L. Shek,et al.  Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. , 2012, Human vaccines & immunotherapeutics.

[13]  J. Farrar,et al.  Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific Meeting. , 2011, Vaccine.

[14]  J. Lang,et al.  Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. , 2011, The American journal of tropical medicine and hygiene.

[15]  Susana Vázquez,et al.  Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. , 2002, Revista panamericana de salud publica = Pan American journal of public health.